journal
MENU ▼
Read by QxMD icon Read
search

Current Pharmaceutical Biotechnology

journal
https://www.readbyqxmd.com/read/28413977/new-suggestions-in-sublingual-immunotherapy-for-house-dust-mite-related-allergic-diseases
#1
Matteo Ferrando, Diego Bagnasco, Giovanni Passa-Lacqua, Francesca Puggioni, Gilda Varricchi, Giorgio Walter Canonica
BACKGROUND: The indications for Allergen immunotherapy (AIT) in patients suffering from House Dust Mite (HDM)-related allergic diseases are presently based on incomplete data. This is essentially based on the fact that HDM allergy is difficult to evaluate in clinical trials, due to the largely variable allergen exposure and symptoms, and to the long periods of observation needed to assess the effects. In addition, at variance with pollen allergy, in HDM allergy asthma is more prevalent...
April 17, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28322160/an-efficient-transient-expression-system-for-enhancing-generation-of-monoclonal-antibodies-in-293-suspension-cells
#2
Guoquan Zhang, Jie Liu, Wanting Fan, Qianyi Chen, Bin Shi
BACKGROUND: Recombinant monoclonal antibodies (mAbs) are useful in research, diagnosis, and therapy. The increased demands of recombinant mAbs require efficient production systems. A variety of expression vectors have been developed for stable or transient production of mAb in mammalian cells. However, though a few commercial expression systems of mAbs can be listened, the high expense often impedes academia researches. METHODS: In this study, we described the development of a transient mammalian system based on a bicistronic vector, which contains internal ribosome entry site (IRES) and enhancer elements to express IgG1 light chain (LC) and heavy chain (HC) in one transcript...
March 20, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28294060/wine-chemical-composition-and-radical-scavenging-activity-of-some-cabernet-franc-clones
#3
Jelena Popović-Djordjević, Boris Pejin, Aleksandra Dramićanin, Sonja Jović, Dragan Vujović, Dragoljub Žunić, Renata Ristić
BACKGROUND: Three clones of Cabernet Franc (Nos. 02, 010 and 012) were selected in the last phase of clonal selection in Serbia. Wines made from each clone were assessed for quality parameters and taste during five consecutive vintages (2008-2012) and compared to the standard. The wine quality was determined based on the following parameters: alcohol, total extract, anthocyanins, tannins, pH, titratable acidity, volatile acidity, aldehydes, esters and reducing sugars, relative density, ash, colour, tonality, and tasting score...
March 13, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28294059/phytochemical-screening-alpha-glucosidase-inhibition-antibacterial-and-antioxidant-potential-of-ajuga-bracteosa-extracts
#4
Kokab Hafeez, Saiqa Andleeb, Tahseen Ghousa, Kalsoom Akhter
BACKGROUND: Ajuga bracteosa, a medicinal herb, used by local community to cure a number of diseases such as inflammation, jaundice bronchial asthma, cancer and diabetes. OBJECTIVES: The aim of present work was to evaluate the antioxidant potential, in vitro antidiabetic and antimicrobial effects of A. bracteosa. METHODS: n-hexane, ethyl acetate, chloroform, acetone, methanol and aqueous extracts of Ajuga bracteosa roots, were prepared via maceration...
March 12, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28240174/hormone-therapy-and-delivery-strategies-against-cardiovascular-diseases
#5
Gayathri Acharya, Nurhasni Hasan, Jin-Wook Yoo, Chi H Lee
This review article is aimed to delineate the potential role of hormones in the treatment and diagnosis of cardiovascular diseases with special emphasis on the nitric oxide (NO) involved mechanisms. This review will also offer an overview on current and future hormone usages, pathophysiology, clinical features, absorption mechanisms and adverse effects. The hormone therapies against cardiovascular diseases as well as their treatment strategies, delivery routes and carriers were thoroughly discussed. Ongoing and future basic and clinical research with hormone will provide important insights into efficient treatment strategies against cardiovascular diseases...
February 23, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28240173/personalized-medicine-of-alcohol-addiction-pharmacogenomics-and-beyond
#6
Vangelis George Manolopoulos, Georgia Ragia
Alcohol addiction or alcoholism is the most severe form of problem drinking. A variety of treatment methods for alcoholism are currently available that combine medications, behavioral treatment and peer support. The drugs that are currently approved by the U.S. Food and Drug Administration (FDA) for treatment of alcohol dependence are disulfiram, naltrexone and acamprosate. For many patients, however, these treatments are not effective. Evidence from a number of different studies suggests that different factors, both psychosocial and economic, as well as genetic variation, are significant contributors to interindividual variation both of clinical presentation of alcohol problems and response to a given treatment...
February 23, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28240172/clinical-applications-of-personalized-medicine-a-new-paradigm-and-challenge
#7
Mariantonia Di Sanzo, Vittorio Fineschi, Marina Borro, Raffaele La Russa, Alessandro Santurro, Matteo Scopetti, Maurizio Simmaco, Paola Frati
The personalized medicine is an emergent and rapidly developing method of clinical practice that uses new technologies to provide decisions in regard to the prediction, prevention, diagnosis and treatment of disease. The continue evolution of technology and the developments in molecular diagnostics and genomic analysis increased the possibility of an even more understanding and interpretation of the human genome and exome, allowing a "personalized" approach to clinical care, so that the concepts of "Systems Medicine" and "System Biology" are increasingly actual...
February 23, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28190384/lactic-acid-bacteria-with-concomitant-il-17-il-23-and-tnf%C3%AE-binding-ability-for-the-treatment-of-inflammatory-bowel-disease
#8
Staša Kosler, Borut Štrukelj, Aleš Berlec
BACKGROUND: Neutralization of proinflammatory cytokines is an established strategy in the treatment of inflammatory bowel disease (IBD). Systemic anti-TNFα antibodies have been used in the clinics for several years, while anti-IL-17/IL-23 antibodies have been less successful so far. We report the development of safe lactic acid bacterium Lb. salivarius with the ability to simultaneously bind IL-17A, IL-23 and TNFα that could be administered orally for the treatment of IBD. METHODS: Three different cytokine-binding non-Ig scaffolds (anti-IL-17A fynomer, anti-IL-23-binding adnectin and anti-TNFα-binding affibody) were cloned and expressed in L...
February 10, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28183244/personalised-healthcare-the-dima-clinical-model
#9
Marina Borro, Giovanna Gentile, Vittorio Fineschi, Zeno Földes-Papp, Paola Frati, Alessandro Santurro, Luana Lionetto, Maurizio Simmaco
Large-scale application of Personalized Medicine requires a multi-disciplinal environment allowing synergic cooperation among different competences. Strict collaboration between medical and medical sciences, as informatics, ethics, politics, are needed to face the challenges of one-sized healthcare. In spite of the increasing interest, how this system can be globally realized remains tentative. Yet, a relatively small, Personalised Healthcare Service is providing a proof-of principle organizational model to guide implementation into clinical practice...
February 8, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28176639/personalized-medicine-in-the-paediatric-population-the-balance-between-pharmacogenetics-progress-and-bioethics
#10
Stefania Schiavone, Margherita Neri, Cristoforo Pomara, Irene Riezzo, Luigia Trabace, Emanuela Turillazzi
Personalized medicine (PM) is becoming increasingly important in contemporary clinical and research scenarios. In the context of PM, pharmacogenomics and pharmacogenetics are aimed at the genetic personalization of drug response. Extrinsic and intrinsic factors may explain inter-individual variability in drug response. Among such factors, age seems to specifically intervene to modulate drug response since normal developmental changes may influence the exposure-response relation. Consequently, the potential benefit of pharmacogenomics (PGx) in the paediatric population is considerable...
February 7, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28176638/personalized-medicine-and-adverse-drug-reactions-the-experience-of-an-italian-teaching-hospital
#11
Raffaele La Russa, Vittorio Fineschi, Mariantonia Di Sanzo, Vittorio Gatto, Alessandro Santurro, Gabriella Martini, Matteo Scopetti, Paola Frati
The personalized medicine is a model of medicine based on inherent difference given by the genetic heritage that characterizes us, diversity that can affect also our response to administered therapy. Nowadays, the term "adverse drug reaction" is identified with any harmful effect involuntary resulting from the use of a medicinal product; pharmacogenomics, in this field, has the aim to improve the drug response and to reduce the adverse reaction. We analyzed all reports of adverse reaction collected in the Pharmacovigilance Centre database of an Italian University Hospital, at the Sant'Andrea Hospital Sapienza University of Rome, in a period of two years...
February 7, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28176637/personalized-medicine-applied-to-forensic-sciences-new-advances-and-perspectives-for-a-tailored-forensic-approach
#12
Alessandro Santurro, Anna Maria Vullo, Marina Borro, Giovanna Gentile, Raffaele La Russa, Maurizio Simmaco, Paola Frati, Vittorio Fineschi
Personalized medicine (PM), included in P5 medicine (Personalized, Predictive, Preventive, Participative and Precision medicine) is an innovative approach to the patient, emerging from the need to tailor and to fit the profile of each individual. PM promises to dramatically impact also on forensic sciences and justice system in ways we are only beginning to understand. The application of omics (genomic, transcriptomics, epigenetics/imprintomics, proteomic and metabolomics) is ever more fundamental in the so called "molecular autopsy"...
February 7, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28164757/bone-micrornas-and-aging
#13
Janja Marc, Barbara Ostanek, Tilen Kranjc
The decline of tissue function in ageing is a consequence of many changes in the gene expression and other extrinsic factors. The molecular mechanisms underlying these changes are heavily investigated with focus on regulation of time-lapse gene expression. microRNAs, short non-coding RNA molecules are among the major regulators of gene expression. microRNAs have been shown to control ageing-related mechanisms and several evidence suggest age-related changes in microRNA transcriptome. However, the source regulator of time-lapse gene expression control still remains unknown...
February 2, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28155605/met-activating-genetically-improved-chimeric-factor-1-promotes-angiogenesis-and-hypertrophy-in-adult-myogenesis
#14
Flavio Ronzoni, Gabriele Ceccarelli, Ilaria Perini, Laura Benedetti, Daniela Galli, Francesca Mulas, Martina Balli, Giovanni Magenes, Riccardo Bellazzi, Gabriella Cusella De Angelis, Maurilio Sampaolesi
BACKGROUND: Myogenic progenitor cells (activated satellite cells) are able to express both HGF and its receptor cMet. After muscle injury, HGF-Met stimulation promotes activation and primary division of satellite cells. MAGIC-F1 (Met-Activating Genetically Improved Chimeric Factor-1) is an engineered protein that contains two human Met-binding domains that promotes muscle hypertrophy. MAGIC-F1 protects myogenic precursors against apoptosis and increases their fusion ability enhancing muscle differentiation...
February 1, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28137221/methoxy-polyethylene-glycol-epoetin-beta-as-a-novel-erythropoiesis-stimulating-agent-with-possible-nephroprotective-and-cardiovascular-protective-effects-in-non-dialysis-chronic-kidney-disease-patients
#15
Piotr Bartnicki, Mariusz Stępień, Jacek Rysz
Chronic kidney disease (CKD) is an important health problem, because of unsuccessful outcomes such as CKD progression to end stage renal disease and high risk of cardiovascular disease (CVD). Anemia, associated with CKD, is considered a non-traditional risk factor for CVD which may contribute to faster CKD progression. Anemia treatment with erythropoiesis-stimulating agents (ESAs) seems to exert non-hematopoietic effects on different tissues and organs, including cardiovascular system and kidneys. On the other hand, clinical use of high doses of short-acting ESAs and higher target hemoglobin level were associated with higher risk of CVD...
January 26, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28137220/multiwalled-carbon-nanotube-chitosan-scaffold-cytotoxic-apoptotic-and-necrotic-effects-on-chondrocyte-cell-lines
#16
Sibel Ilbasmis-Tamer, Hakan Çiftçi, Mustafa Tu Rk, Tuncer Degim, Uğur Tamer
BACKGROUND: Carbon nanotubes (CNTs) have been considered highly successful and proficient in terms of their mechanical, thermal and electrical functionalization and biocompatibility. In regards to their significant extent in bone regeneration, it has been determined that CNTs hold the capability to endure clinical applications through bone tissue engineering and orthopedic procedures. In the present study, we report on a composite preparation, involving the use of CNT-chitosan as scaffold for bone repair and regeneration...
January 26, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28117005/pharmacogenomic-challenges-in-cardiovascular-diseases-examples-of-drugs-and-considerations-for-future-integration-in-clinical-practice
#17
Jérôme Chatelin, Maria G Stathopoulou, Alex-Ander Aldasoro Arguinano, Ting Xie, Sophie Visvikis-Siest
Introduction Even if cardiovascular disease (CVD) drugs are supported by high level proofs, the results of CVD treatment present great disparities: there are still patients dying with supposed optimal treatment, patients facing adverse events and CVD remain the primary cause of death in the world. Pharmacogenomics is the basis of personalisation of the treatment able to allow higher medication success rates. In this review, we will present detailed examples of CVD drugs to highlight the complexity of this challenging field and we will discuss novel concepts that should be considered for a fastest integration of pharmacogenomics in clinical practice of CVD...
January 23, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28056729/editorial-molecular-cellular-and-pharmaceutical-aspects-of-biomaterials-in-dentistry-and-oral-and-maxillofacial-surgery-international-cooperation-translational-research-and-transdisciplinarity
#18
D M Dohan Ehrenfest, Lidia M Wisniewska, Agata Cieslik-Bielecka, Hom-Lay Wang, Manuel Fernándes-Cruz
No abstract text is available yet for this article.
January 4, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28056728/antimicrobial-effectiveness-of-synthesized-bioactive-silver-nanoparticles-by-the-actinomycetes-hgg16n-strain
#19
Bogusław Buszewskia, Viorica Railean-Plugarua, Paweł Pomastowski, Katarzyna Rafińskaa, Malgorzata Szultka-Mlynskaa, Tomasz Kowalkowskia
BACKGROUND: Biologically synthetized silver nanoparticles are promising antimicrobial agent. Flow cytometry, well diffusion methods, colony-forming units (CFU) and spectroscopic approach are commonly used in antimicrobial study. The aims of this study were to provides information about effectiveness of BioAgNPs synthesized by Actinomycetes HGG16n using fluorescence flow cytometry method as an alternative to the standard ones (well and disc diffusion method). METHODS: It was applied flow cytometry technique to monitor the antibacterial effect of biocolloidal silver and its combination with various commercial antibiotics against selected pathogens...
January 4, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/28044932/ubiquitous-pharmacogenomics-u-pgx-the-time-for-implementation-is-now-an-horizon2020-program-to-drive-pharmacogenomics-into-clinical-practice
#20
Erika Cecchin, Rossana Roncato, Hendrik Jan Guchelaar, Giuseppe Toffoli, and for the Ubiquitous Pharmacogenomics Consortium
Although the clinical validity of a number of pharmacogenetic markers is nowadays a matter of fact, and led authoritative scientific consortia as the Dutch Pharmacogenetic Working Group (DPWG) and the Clinical Pharmacogenomics Implementation Consortium (CPIC) to publish pharmacogenetic guidelines, the clinical implementation in the real life remains challenging. Ubiquitous Pharmacogenomics (U-PGx) program is a coordinated effort that put together scientific and clinical expertise in the pharmacogenomic field, to implement the pre-emptive pharmacogenomic approach in the clinical practice in Europe, and to demonstrate its benefit in both patients clinical outcome and quality of life, with an economic advantage for the healthcare system...
January 2, 2017: Current Pharmaceutical Biotechnology
journal
journal
35110
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"